The Radgil2 x-ray irradiator continues its journey for the second consecutive year at the annual AABB congress, the American Association of Blood Bankers in San Antonio – Texas.
A strategic opportunity for the company, to oversee the market and introduce the product as a substitute for gamma-ray irradiators with Cs137 sources.
Gilardoni’s equipment, already modified to comply with US standards, is about to obtain the FDA certification that is expected by mid-2020.
Given the geographical location of San Antonio, Texas, the Annual AABB Meeting was a useful opportunity to meet, in addition to many US operators, also South American and Canadian customers.
Radgil2 is an X-ray irradiator indicated for the prevention of TA-GvHD, a rare disease caused by donor T lymphocytes, placed in the recipient following a transfusion. It is also used in research for the irradiation of cells, tissues and culture media.
